Drug Profile
Razupenem
Alternative Names: PTZ601; PZ-601; SM-216601; SMP-216601; SMP-601Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Dainippon Sumitomo Pharma; Protez Pharmaceuticals
- Class Antibacterials; Carbapenems; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Gram-positive infections
- Discontinued Gram-negative infections; Nosocomial infections; Skin and soft tissue infections
Most Recent Events
- 22 May 2012 No development reported - Preclinical for Bacterial infections in Japan (IV)
- 22 May 2012 No development reported - Preclinical for Gram-positive infections in Japan (IV)
- 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Gram-positive and Gram-negative infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)